In-Vivo CAR T Cell Breakthrough—But How Far From Patients?

For patients with aggressive blood cancers, CAR T-cell therapy has been a lifeline—but its reliance on extracting, engineering, and reinfusing a patient’s own immune cells creates logistical hurdles. Now, scientists have demonstrated a two-vector system that generates CAR T cells directly inside the body, bypassing the need for external manipulation. In preclinical models, the approach showed efficacy against acute leukemia, multiple myeloma, and even a solid tumor—a notable expansion beyond CAR T’s traditional domain.

The study, reported in Genetic Engineering & Biotechnology News, used a dual-adeno-associated virus (AAV) strategy: one vector to insert the CAR receptor gene, another to drive its expression in T cells. Early results suggest the system can produce functional CAR T cells in vivo with anti-tumor activity. But as with all preclinical work, the leap from mouse models to human biology remains untested.

What makes this approach intriguing is its potential to simplify CAR T production. Current therapies like Kymriah or Yescarta require weeks of personalized manufacturing. An in-vivo method could, in theory, reduce costs and delays. Yet theory and practice are separated by rigorous testing.

The evidence grade here is preclinical only. While the dual-vector system produced measurable anti-tumor effects in mice, the study’s sample size and duration were limited. Solid tumors, in particular, have historically resisted CAR T therapies due to their immunosuppressive microenvironments; whether this method overcomes that barrier in humans is unknown.

Regulatory status is equally early. No clinical trials are listed on ClinicalTrials.gov for this specific approach, and the AAV delivery system itself carries risks—including potential off-target effects or immune reactions to the viral vectors. The FDA’s 2022 guidance on gene therapy underscores the need for long-term safety data, a hurdle this research has yet to clear.

For patients today, nothing changes. Existing CAR T therapies remain the standard for eligible blood cancers, with all their limitations. The true test of this dual-vector system will be in Phase I trials, where dosing, safety, and the durability of in-vivo-generated CAR T cells can be assessed. Even then, solid tumors—a far tougher target—would require separate validation.

The broader question is whether this simplifies CAR T or introduces new complexities. Viral vectors add layers of biological uncertainty, and in-vivo editing raises concerns about uncontrolled immune activation. As one immunologist noted in Nature Reviews Cancer, ‘The elegance of in-vivo generation is matched only by the complexity of ensuring it works only as intended.’